Vaginal Discharge in the Emergency Department: Essential MRCEM SBA Practice Questions Explained

Vaginal discharge is a deceptively straightforward presenting complaint that conceals a wide and clinically significant differential, from benign physiological variation through to pelvic inflammatory disease (PID) carrying long-term sequelae including infertility and chronic pelvic pain. For UK emergency trainees, it sits squarely within the RCEM curriculum as a gynaecological emergency medicine competency, and it is precisely the kind of scenario that appears in MRCEM SBA practice questions because it demands systematic clinical reasoning, knowledge of current UK guidelines, and sound disposition judgement. Getting the diagnosis wrong in the exam, as in clinical practice, has consequences.

Clinical Context and Epidemiology

Vaginal discharge accounts for a meaningful proportion of gynaecological attendances in UK emergency departments, disproportionately affecting women under 25 years of age. The demographic overlap with the highest-risk groups for sexually transmitted infections is not incidental. Public Health England data consistently demonstrate that chlamydia and gonorrhoea incidence is highest in women aged 15 to 24, and many of these women present first to the ED rather than to primary care or GUM services. The Emergency Medicine clinician is therefore frequently the first point of diagnostic contact.

Beyond STIs, BV is the commonest cause of abnormal vaginal discharge in women of reproductive age globally, and VVC affects approximately 75 percent of women at some point in their lives. PID, however, commands the greatest clinical urgency: it affects an estimated 1 in 50 women aged 16 to 44 in the UK, and delayed or inadequate treatment is associated with a significantly increased risk of ectopic pregnancy, tubal factor infertility, and chronic pelvic pain, as outlined in NICE clinical guidance on pelvic inflammatory disease. This is the condition the examiners are most likely to probe.

Pathophysiology: The Science Behind the Discharge

Normal vaginal physiology is dominated by Lactobacillus species, which produce lactic acid and hydrogen peroxide, maintaining a vaginal pH between 3.8 and 4.5. This acidic environment is intrinsically hostile to most pathogens. Any disruption to this ecosystem creates conditions favouring dysbiosis or pathogenic colonisation.

Bacterial Vaginosis

BV results from replacement of the normal Lactobacillus-dominant flora by a polymicrobial consortium including Gardnerella vaginalis, Mobiluncus species, Prevotella species, and other anaerobes. Critically, BV is not a true vaginitis because it does not elicit a classical inflammatory response; there is no significant neutrophilic infiltrate. The vaginal pH rises above 4.5, volatile amines are produced by anaerobic metabolism, and microscopy reveals characteristic clue cells (vaginal epithelial cells coated with adherent coccobacilli). Clinically this translates to a thin, homogeneous, grey-white discharge with a fishy odour that is particularly marked after intercourse or during menstruation when alkaline semen or blood raises the pH further.

Vulvovaginal Candidiasis

VVC arises when Candida species, most commonly Candida albicans in 80 to 90 percent of cases, transition from commensal colonisation to symptomatic infection. Predisposing factors include recent broad-spectrum antibiotic use (which reduces competing lactobacilli), immunosuppression, poorly controlled diabetes mellitus, pregnancy, and corticosteroid therapy. The host inflammatory response is vigorous, producing the hallmark features of vulval erythema, oedema, pruritus, dysuria, and a thick, white, cottage cheese-like discharge. pH is typically normal (below 4.5), which is a useful discriminator on microscopy and a favourite exam differentiator.

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan transmitted sexually. It elicits a true inflammatory vaginitis, disrupts normal lactobacilli, and raises vaginal pH above 4.5. The classic discharge is described as offensive, frothy, and yellow-green, though clinical presentation is highly variable and up to 50 percent of infected women are asymptomatic. The strawberry cervix (colpitis macularis) is pathognomonic but present in fewer than 5 percent of cases clinically, making microscopy or NAAT testing the diagnostic mainstay.

Pelvic Inflammatory Disease

PID develops when lower genital tract pathogens, most often Chlamydia trachomatis, Neisseria gonorrhoeae, or endogenous anaerobes and facultative aerobes, ascend to infect the endometrium, fallopian tubes, and potentially the peritoneum and adjacent structures. The ensuing salpingitis and endometritis produce pelvic pain, uterine tenderness, cervical motion tenderness (the most specific examination finding), adnexal tenderness, and systemic features of infection. Tubo-ovarian abscess (TOA) represents a severe complication requiring urgent imaging and frequently inpatient management.

ED Assessment and Management

History

A structured history should cover: the character, colour, consistency, odour, and duration of the discharge; associated symptoms including pelvic or abdominal pain, dyspareunia, post-coital or intermenstrual bleeding, dysuria, and fever; last menstrual period and contraceptive history; sexual history including number of recent partners, condom use, and any prior STI; and obstetric history. Always document immunosuppression, recent antibiotic use, and any relevant medication including corticosteroids. Safeguarding considerations must be active in any consultation involving sexual health, particularly where there is a possibility of non-consensual intercourse or where the patient is under 18.

Examination

Vital signs inform acuity. Pyrexia, tachycardia, and hypotension suggest systemic infection or a complication such as TOA or peritonitis. Abdominal examination assesses peritonism. Speculum examination documents the character of the discharge, the state of the vaginal walls and cervix (including any contact bleeding or ectropion), and allows sampling. Bimanual examination assesses uterine size, cervical motion tenderness, and adnexal masses. Cervical motion tenderness in the context of abnormal discharge should prompt immediate consideration of PID.

Investigations

Core investigations in the ED should include: a urine pregnancy test before any other assessment is interpreted; high vaginal swab (HVS) for microscopy and culture targeting BV, candida, and trichomonas; endocervical swabs or self-taken vulvovaginal swabs for NAAT testing for chlamydia and gonorrhoea; point-of-care tests where available; urinalysis and urine culture to exclude urinary tract infection; and FBC, CRP, and blood cultures if systemic infection is suspected. Pelvic ultrasound (transabdominal or transvaginal) is indicated if TOA is suspected or if there is diagnostic uncertainty around an adnexal mass. The NICE Clinical Knowledge Summaries on pelvic inflammatory disease provide detailed investigation and management pathways relevant to clinical practice and exam preparation alike.

Management by Condition

BV: Metronidazole 400 mg orally twice daily for 5 to 7 days, or metronidazole 2 g orally as a single dose, or topical metronidazole 0.75% gel as an alternative. Alcohol should be avoided during and for 48 hours after metronidazole therapy. Clindamycin 2% vaginal cream is an alternative for those unable to tolerate metronidazole. Treatment of male partners is not recommended.

VVC: For uncomplicated episodes, a single dose of oral fluconazole 150 mg or a topical azole (e.g. clotrimazole pessary 500 mg as a single dose) is first-line, as confirmed in the British National Formulary. Caution is required with fluconazole in pregnancy (avoid oral formulations in the first trimester). Topical preparations are preferred in pregnancy.

Trichomoniasis: Metronidazole 400 mg twice daily for 5 to 7 days (preferred for superior cure rates over single-dose 2 g regimen). Partner treatment is mandatory given the sexually transmitted nature. GUM referral should be arranged for partner notification.

PID: Empirical antibiotic therapy should not await swab confirmation. BASHH guidelines recommend outpatient treatment for mild to moderate PID with oral ofloxacin 400 mg twice daily plus oral metronidazole 400 mg twice daily for 14 days, or intramuscular ceftriaxone 500 mg single dose followed by oral doxycycline 100 mg twice daily plus metronidazole 400 mg twice daily for 14 days. Inpatient parenteral therapy is indicated for severe PID, suspected TOA, pregnancy, failure of oral therapy, or diagnostic uncertainty requiring exclusion of surgical pathology. Analgesia, sexual abstinence advice, and urgent GUM follow-up are integral to the management plan.

How the MRCEM SBA Exam Tests This Topic

Within the RCEM curriculum, gynaecological presentations including vaginal discharge are mapped to the domain of undifferentiated abdominal and pelvic pain and to sexual and reproductive health. MRCEM SBA practice questions on this topic characteristically present a clinical vignette of a woman of reproductive age with discharge and ask candidates to identify the most likely diagnosis, the single best investigation, or the most appropriate first-line treatment. Common question structures include:

• A vignette describing thin, grey-white, fishy-smelling discharge with a pH of 5.0 and clue cells on wet mount, asking for the diagnosis (BV) or treatment (metronidazole).
• A scenario of a 22-year-old with bilateral lower abdominal pain, cervical motion tenderness, and purulent cervical discharge, asking whether to treat empirically now or await swab results (treat now, PID is a clinical diagnosis).
• A question asking about the most appropriate investigation to exclude ectopic pregnancy in a woman presenting with discharge and pelvic pain (urine pregnancy test, not ultrasound, as the first step).
• A question probing knowledge of antibiotic choice in pregnancy, testing whether the candidate knows that oral fluconazole is avoided in the first trimester and that metronidazole is used cautiously but remains appropriate for BV in pregnancy.

Examiners also probe understanding of safeguarding, partner notification responsibilities, and the threshold for GUM referral. These non-pharmacological management steps are systematically undervalued by candidates who focus exclusively on antibiotic regimens. The MRCEM SBA clinical scenarios in this domain reward integrated, guideline-literate reasoning rather than pattern recognition alone.

Revision Pearls: High-Yield Facts for the Exam

1. The Amsel criteria for BV require three of four features: homogeneous white-grey discharge, vaginal pH above 4.5, positive amine (whiff) test with 10% KOH, and clue cells on microscopy exceeding 20 percent of epithelial cells.
2. VVC pH is typically below 4.5, which distinguishes it from BV and trichomoniasis on a microscopy vignette.
3. PID is a clinical diagnosis. Treat empirically on the basis of cervical motion tenderness, uterine tenderness, or adnexal tenderness in a sexually active woman with lower abdominal pain or discharge. Do not wait for swab results.
4. Neisseria gonorrhoeae requires culture on specialist media (e.g. Thayer-Martin agar) in addition to NAAT because sensitivity testing for antibiotic resistance is clinically critical; NAAT alone does not provide susceptibility data.
5. Ceftriaxone 500 mg intramuscularly (increased from the historic 250 mg dose in updated BASHH guidance) is now the recommended dose for uncomplicated gonorrhoea in the UK due to emerging antimicrobial resistance.
6. TOA should be suspected when a pelvic mass is palpable or when a patient with presumed PID fails to improve within 72 hours of appropriate antibiotics. Ultrasound is the first-line imaging modality.
7. Alcohol interaction with metronidazole (disulfiram-like reaction) is a frequently tested pharmacological point in MRCEM SBA exam questions; patients must be clearly counselled.
8. Chlamydia trachomatis is the commonest bacterial STI in the UK and is frequently asymptomatic; a normal examination does not exclude it.

Common Pitfalls: Where Candidates Lose Marks

• Failing to order a urine pregnancy test as the first investigation in any woman of reproductive age with pelvic symptoms.
• Awaiting swab results before initiating empirical antibiotics for PID, missing the clinical imperative to treat promptly.
• Selecting fluconazole for VVC in a pregnant patient without recognising the teratogenicity risk of systemic azoles in the first trimester.
• Confusing the single-dose (2 g) versus five-day metronidazole regimen and when each is preferred (five-day course is preferred for trichomoniasis).
• Overlooking the need for partner notification and GUM referral as part of the management plan, treating it as someone else’s responsibility rather than an ED obligation.
• Misattributing symptoms of early ectopic pregnancy or appendicitis to a primary vaginal infection, failing to maintain a broad differential when abdominal pain is prominent.
• Not recognising the increased gonorrhoea ceftriaxone dose in updated guidance, selecting the outdated 250 mg dose in a treatment question.

How EM Learning Centre Supports Your MRCEM Single Best Answer Revision

Gynaecological presentations such as vaginal discharge represent exactly the kind of multidisciplinary, guideline-dependent topic that rewards structured, evidence-based revision. The MRCEM Single Best Answer revision course at EM Learning Centre covers the full breadth of the RCEM curriculum, including sexual and reproductive health, with exam-quality single best answer questions mapped to current BASHH, NICE, and RCEM guidance. Each question comes with a detailed explanation anchored to authoritative sources, so you understand not just what the answer is but why, and why the distractors are wrong.

If you are working through MRCEM SBA practice questions on gynaecological emergencies, pharmacology, or any other domain and finding gaps in your knowledge, the structured lessons and question bank on the EM Learning Centre homepage are designed specifically to close those gaps efficiently. Every explanation is written at consultant level, without oversimplification, because the exam demands that standard and so does your future practice.

References

1. National Institute for Health and Care Excellence. Pelvic inflammatory disease. NICE Clinical Knowledge Summaries. NICE Clinical Knowledge Summaries
2. National Institute for Health and Care Excellence. Vaginal discharge. NICE Clinical Knowledge Summaries. NICE Clinical Knowledge Summaries
3. British National Formulary. Antifungal preparations; Metronidazole. British National Formulary (BNF)
4. Royal College of Emergency Medicine. Emergency Medicine Curriculum. Royal College of Emergency Medicine
5. BMJ Best Practice. Bacterial vaginosis; Pelvic inflammatory disease. The BMJ
6. NHS. Pelvic inflammatory disease: overview and treatment. NHS